Mirum Pharmaceuticals (MIRM) · maralixibat
Earlier window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2027
top-line data from the Phase 3 Livmarli EXPAND clinical trial for the treatment of other ultra-rare cholestatic pruritus indications, the Phase 2b volixibat clinical trial for the treatment of primary biliary cholangitis and the Phase 2 clinical trial of MRM-3379 for the treatment of Fragile-X Syndrome in 2027
· filed · SEC filing
After
Stated timing: Q4 2026
LIVMARLI ® EXPAND study in additional cholestatic pruritus settings timing accelerated; topline data now expected Q4 2026
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/MIRM-maralixibat-2026-01-12, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/MIRM-maralixibat-2026-01-12
Mirum Pharmaceuticals (MIRM) pipeline and stated timing · Calendar · Companies A–Z
A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.